Discover Andy Brown's long and arduous journey battling a type of non-Hodgkin lymphoma and how a clinical trial altered his ...

See why investor confidence in cell and gene therapies now depends on execution and supply chain strategy—not strong science ...

Not a lot went down on the biotech deals front in August 2026, but it did see sustained collaboration in oncology and ...

The companies Moderna, Amylyx Pharmaceuticals, and Braveheart Bio bagged the biggest biotech funding rounds overall in August ...

Discover six MASH companies to keep an eye on as the race to shape the next generation of liver disease therapies heats up.

Cytokinetics’ aficamten has become the first cardiac myosin inhibitor to succeed in a phase 3 trial in non-obstructive hypertrophic cardiomyopathy (HCM), potentially opening a new treatment option for ...

The concept of targeted therapeutics is often traced back to German Nobel laureate Paul Ehrlich’s “magic bullet” in 1907, which envisioned a single entity that could both recognize a disease target ...

Home to excellent research institutions, a thriving life sciences community, a strong collaborative culture, and a strategic location at the heart of Europe, Ghent is now investing in cutting-edge ...

As U.S. budget cuts and freezes push healthcare and biopharma research in the States towards uncertainty, could Europe be the destination that science talent flocks towards? That’s what the European ...

For decades, cystic fibrosis has remained a relentless, life-limiting disease. But now, the future of cystic fibrosis care could be shifting from symptom management to something far more revolutionary ...

Keep up with biotech layoffs in 2025! Each week, the Labiotech team tracks and analyzes layoffs across the biotech industry, offering a clear, data-driven view of trends affecting companies, ...

Christophe Le Tourneau discussing precision medicine studies at ASCO 2017 SHIVA01 was a multicentric Phase II trial that compared targeted therapy based on tumor molecular profiling versus ...